These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6128757)

  • 41. Treatment of tardive dyskinesia: use of dopamine-depleting agents.
    Fahn S
    Clin Neuropharmacol; 1983 Jun; 6(2):151-8. PubMed ID: 6133619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
    Allen RM
    Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tardive dyskinesia: review and update.
    Klawans HL; Goetz CG; Perlik S
    Am J Psychiatry; 1980 Aug; 137(8):900-8. PubMed ID: 6106395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2001; (2):CD000203. PubMed ID: 11405955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder.
    Steiner W; Laporta M; Chouinard G
    Acta Psychiatr Scand; 1990 May; 81(5):437-40. PubMed ID: 1972608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Receptor-cell sensitivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia.
    Friedhoff AJ; Rosengarten H; Bonnet K
    Psychopharmacol Bull; 1978 Oct; 14(4):77-9. PubMed ID: 704769
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Symptomatic treatment of tardive dyskinesia: a word of caution.
    Kucharski LT; Unterwald EM
    Schizophr Bull; 1981; 7(4):571-3. PubMed ID: 6798690
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of two iatrogenic dyskinesias.
    Karson CN; Jeste DV; LeWitt PA; Wyatt RJ
    Am J Psychiatry; 1983 Nov; 140(11):1504-6. PubMed ID: 6137963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paradoxical response to dopamine agonists in tardive dyskinesia.
    Carroll BJ; Curtis GC; Kokmen E
    Am J Psychiatry; 1977 Jul; 134(7):785-9. PubMed ID: 17308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
    World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Striatal dopamine D2 receptors in tardive dyskinesia: PET study.
    Blin J; Baron JC; Cambon H; Bonnet AM; Dubois B; Loc'h C; Mazière B; Agid Y
    J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1248-52. PubMed ID: 2574230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa.
    Hardie RJ; Lees AJ
    J Neurol Neurosurg Psychiatry; 1988 Jun; 51(6):850-4. PubMed ID: 2900293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.